Side-by-Side Comparison
CJC-1295 vs MK-677: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how CJC-1295 and MK-677 differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
CJC-1295
L3Also: CJC-1295 DAC, CJC-1295 without DAC, Modified GRF 1-29
A growth hormone-releasing hormone (GHRH) analog studied for its ability to increase growth hormone and IGF-1 levels.
MK-677
L4Also: Ibutamoren, Nutrobal, L-163,191
An oral ghrelin mimetic (not a peptide) that stimulates growth hormone release. Has extensive human data but has not achieved FDA approval.
Side-by-side comparison
| Attribute | CJC-1295 | MK-677 |
|---|---|---|
| Primary mechanism | GHRH Receptor Agonism | Oral Ghrelin Receptor Agonism |
| FDA status | Banned from Compounding (Category 2) | Research Only |
| Evidence level | Emerging Clinical Evidence | Strong Clinical Evidence |
| Human trials | Yes (3+ indexed) | Yes (15+ indexed) |
| Studies indexed | 24 total (5 human, 12 animal) | 75 total (25 human, 30 animal) |
| Primary uses researched | Growth hormone release, Body composition, Recovery | Growth hormone release, Sleep quality, Appetite stimulation, Bone density (research) |
| Administration routes | subcutaneous | oral |
| Molecular weight | 3367.97 Da | 528.67 Da |
| Amino acids | 30 | — |
| Category | growth hormone | growth hormone |
| WADA status | Prohibited | Prohibited |
Key differences
Mechanism. CJC-1295 acts primarily through ghrh receptor agonism, while MK-677 acts primarily through oral ghrelin receptor agonism. This means they address different biological pathways even when targeting overlapping clinical goals.
Regulatory status. CJC-1295 is classified as banned from compounding (category 2); MK-677 is classified as research only. Regulatory status drives availability, legality, and the standard of evidence required for specific therapeutic claims.
Evidence base. MK-677 sits at a higher evidence level (L4) than CJC-1295 (L3) under PeptideMark's L1–L5 methodology.
Research focus. Published research on CJC-1295 has concentrated on growth hormone release, body composition, recovery. Research on MK-677 has concentrated on growth hormone release, sleep quality, appetite stimulation. There is meaningful overlap between the two research programs, which is why these compounds are frequently compared.
Safety snapshot
| Attribute | CJC-1295 | MK-677 |
|---|---|---|
| Documented effects | 8 total | 9 total |
| Serious events | 0 | 0 |
| Common events | 2 | 4 |
| Black box warning | No | No |
| Contraindications | 4 listed | 4 listed |
| Drug interactions | 2 flagged | 2 flagged |
| Most common event | Injection site reactions | Increased appetite |
Strengths & limitations
CJC-1295
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Restricted from compounding pharmacies (FDA Category 2)
- Prohibited in competitive sport under WADA
MK-677
Strengths
- Strong evidence base (L4)
- Multiple human clinical trials (15+ indexed)
Limitations
- Not FDA-approved for any indication — research use only
- Prohibited in competitive sport under WADA
Representative studies
CJC-1295
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL, Neale A, Lawrence B, et al. · Journal of Clinical Endocrinology & Metabolism (2006)
CJC-1295 DAC produced dose-dependent, sustained increases in GH and IGF-1 with cumulative effects from repeated dosing — the foundational human pharmacokinetic data.
PubMed 16352683Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Ionescu M, Bhatt DL. · Journal of Clinical Endocrinology & Metabolism (2006)
CJC-1295 preserves pulsatile GH secretion during continuous stimulation — the enhanced trough GH levels (not pulse amplitude) drive the IGF-1 increase.
PubMed 17018654MK-677
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism
Murphy MG, Plunkett LM, Gertz BJ, et al. · Journal of Clinical Endocrinology & Metabolism (1998)
MK-677 25mg daily reversed diet-induced nitrogen wasting by increasing GH pulse amplitude and IGF-1 levels.
PubMed 9467534Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial
Nass R, Pezzoli SS, Oliveri MC, et al. · Annals of Internal Medicine (2008)
MK-677 increased GH and IGF-1 to youthful levels for 12 months but did not improve strength or function, and insulin sensitivity declined significantly.
PubMed 18981485Frequently asked
What is the main difference between CJC-1295 and MK-677?
CJC-1295 is a growth hormone-releasing hormone (ghrh) analog studied for its ability to increase growth hormone and igf-1 levels. Its primary mechanism is ghrh receptor agonism. MK-677 is an oral ghrelin mimetic (not a peptide) that stimulates growth hormone release. has extensive human data but has not achieved fda approval. Its primary mechanism is oral ghrelin receptor agonism. The two differ in regulatory status (Banned from Compounding (Category 2) vs Research Only), strength of evidence (L3 vs L4), and the primary conditions for which each is researched.
Is CJC-1295 or MK-677 FDA approved?
CJC-1295: Placed on FDA Category 2 list. Not approved for human use. Previously available from compounding pharmacies as a growth hormone secretagogue. MK-677: Not FDA-approved. Non-peptide ghrelin mimetic (not technically a peptide, but commonly grouped with peptides). Has failed in clinical trials for growth hormone deficiency.
How does the evidence base compare?
CJC-1295 has 24 indexed studies (5 human, 12 animal) and is rated Emerging Clinical Evidence. MK-677 has 75 indexed studies (25 human, 30 animal) and is rated Strong Clinical Evidence. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can CJC-1295 and MK-677 be compared directly?
Yes — both compounds share the growth hormone category, meaning head-to-head comparisons are meaningful for the same therapeutic targets. Direct head-to-head trials between peptides are rare, however, so most comparisons rely on separate trial datasets rather than direct RCT data.
Are CJC-1295 and MK-677 commonly stacked together?
There is no widely documented stacking protocol combining CJC-1295 and MK-677 in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, CJC-1295 or MK-677?
CJC-1295 has 8 documented side effects (0 serious). MK-677 has 9 documented side effects (0 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are CJC-1295 and MK-677 administered?
CJC-1295 is typically administered via subcutaneous. MK-677 is typically administered via oral. Route differences affect onset, peak levels, and patient convenience.
Which is better, CJC-1295 or MK-677?
"Better" depends on the therapeutic goal, regulatory context, and individual response. CJC-1295 is most researched for growth hormone release and body composition; MK-677 is most researched for growth hormone release and sleep quality. FDA status also matters: Banned from Compounding (Category 2) for CJC-1295 vs Research Only for MK-677. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
CJC-1295 →
Full profile
MK-677 →